Dr. Westin received her doctorate of Medicine from the University of Florida College of Medicine.  She completed Obstetrics and Gynecology residency at the University of North Carolina – Chapel Hill and fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.  During fellowship, she received an MPH with a concentration in epidemiology from the University of Texas, School of Public Health. In addition to her training in Gynecologic Oncology, she also completed a short fellowship in Investigational Cancer Therapeutics.  She joined the faculty at The University of Texas MD Anderson Cancer Center in 2010. She has been honored as a K12 scholar, Andrew Sabin Family Fellow, CURE Magazine Ovarian Cancer Hero and a Gynecologic Oncology Group (GOG) Foundation Scholar Investigator.Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Medical Director of the Gynecologic Oncology Center, Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees.  She is the co-PI for five major projects in her institution’s SPORE in Uterine Cancer and SPORE in Ovarian Cancer.  In addition, she is currently the PI or co-PI for greater than 15 novel treatment trials in gynecologic malignancies. Most recently, she served as the global principal investigator for the GOG3041/DUO-E phase III clinical trial exploring the addition of immunotherapy and PARP inhibitors to chemotherapy in advanced/recurrent endometrial cancer. Dr. Westin has authored or co-authored greater than 200 scientific publications, book chapters and invited articles. She has been invited to lecture as an expert on clinical trials, genomic testing and targeted therapy in gynecologic malignancies in national and international venues.